Sodium-glucose cotransporter 2 inhibitors as potential anticancer agents
Oncological diseases are one of the leading causes of mortality in the world. Despite the intensive search for new methods to increase the efficacy and safety of antineoplastic therapy and to reduce resistance to it by malignant tumors, treatment issues still remain unresolved in clinical oncology....
Saved in:
| Main Authors: | E. R. Radkevich, A. S. Severina, M. S. Shamkhalova, M. V. Shestakova |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2025-05-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/13224 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Sodium-glucose cotransporter 2 inhibitor for the treatment of diabetic nephropathy
by: Kong Ling-li, et al.
Published: (2021-01-01) -
Sodium-Glucose Cotransporter-2 Inhibitor in Diabetic and Nondiabetic Renal Transplant Recipients
by: Lucie Maigret, et al.
Published: (2025-03-01) -
Perioperative euglycemic DKA: The YIN and YANG of sodium-glucose cotransporter 2 inhibitors
by: Shilpushp Bhosale, et al.
Published: (2025-01-01) -
Association of sodium-glucose cotransporter-2 inhibitor use and mortality in patients with endometrial cancer: a retrospective cohort study
by: Min Wang, et al.
Published: (2025-07-01) -
The role of sodium – glucose cotransporter-2 inhibitors in the treatment of different phenotypes of chronic heart failure
by: M. Yu. Kolesnyk, et al.
Published: (2024-03-01)